Carcinotech and CELLINK have partnered to jointly develop protocols for the biofabrication of 3D bioprinted tumor models. This is expected to accelerate and improve drug development accuracy and processes.
Globally, an estimated 19.3 million cancer cases and nearly 10 million cancer deaths were recorded in 2020. A fact that underscores the urgency to develop effective therapeutic approaches and drugs. Current therapeutic options vary widely in efficacy and are limited in number.
Carcinotech has established itself as a pioneer in the production of 3D bio-printed micro-tumors and 3D models based on cancer cell lines. Utilizing CELLINK’s technology for automated workflows – a fine-tuning that has been perfected over the past three years – the company has been instrumental in supporting pharmaceutical research.
“We are looking forward to seeing the impact of this partnership on the oncology research community and look forward to the advancements that will be made in cancer research through the use of Carcinotech’s optimized cancer models. Combining Carcinotech’s in depth understanding of cancer, and CELLINK’s BIO CELLX system’s precision and reproducibility, we hope to provide a new degree of efficiency to cancer research workflows,” said Cecilia Edebo, CEO CELLINK.
The protocols, which will be available on CELLINK’s BIO CELLX system, use cell line-based 3D models and are designed to significantly accelerate research timelines. In doing so, the 3D cancer cell line models were developed to integrate the physiologically representative ratio of five key cell types relevant to each cancer type with widely available cell lines.
Part of this collaboration is that the developed protocols will be made available on CELLINK’s BIO CELLX 3D biodispenser. In doing so, the BIO CELLX stands ready as an outstanding biodispenser system that offers customers the ability to automate 3D cell culture workflows.
This collaboration is not the first of its kind between CELLINK and Carcinotech. Back in 2020, the companies allied to further advance 3D bio-printing technology for cancer research, leveraging Carcinotech’s extensive expertise in patient-derived tumor replicas and CELLINK’s innovative bio-inks.
“We are excited to continue working with CELLINK, a global leader in 3D bioprinting. Their unique technology as well as high quality bioink, provide revolutionary capabilities to the wider life science and drug discovery market. Their extensive knowledge in 3D bioprinting combined with our expertise in oncology and 3D modelling will help fulfil our shared commitment to accelerate oncology drug development pipelines,” said Ishani Malhotra, CEO and Founder of Carcinotech.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
